Common use of ENS Diligence and Reporting Clause in Contracts

ENS Diligence and Reporting. 5.1.1. At all times during the term of this Agreement, but subject to ROCHE’s exercise of the First Option or the Second Option, ENS will use and will cause its Affiliates, sub-licensees and marketing partners (if any) to use Commercially Reasonable Efforts to proceed with the development, manufacture, marketing, distribution and sale of the Compound and/or Product. *Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC.

ENS Diligence and Reporting. 5.1.1. 4.1.1 At all times during the term of this Agreement, but subject to ROCHE’s exercise of the First Option or the Second Option, ENS will use and will cause its Affiliates, sub-licensees and marketing partners (if any) to use Commercially Reasonable Efforts to proceed with the development, manufacture, marketing, distribution and sale of the Compound and/or Product. ** Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC.

ENS Diligence and Reporting. 5.1.1. At all times during the term of this Agreement, but subject to ROCHE’s exercise of the First Option or the Second Option, ENS will use and will cause its Affiliates, sub-licensees and marketing partners (if any) to use Commercially Reasonable Efforts to proceed with the development, manufacture, marketing, distribution and sale of the Compound and/or Product. “*Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC.”

ENS Diligence and Reporting. 5.1.1. 4.1.1 At all times during the term of this Agreement, but subject to ROCHE’s exercise of the First Option or the Second Option, ENS will use and will cause its Affiliates, sub-licensees and marketing partners (if any) to use Commercially Reasonable Efforts to proceed with the development, manufacture, marketing, distribution and sale of the Compound and/or Product. *“* Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC.”